Clinical trial
A Phase 2 Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer Who Have Received Two or Three Prior Systemic Chemotherapy Regimens
NCT05513742 is registered in ClinicalTrials.gov with Compass Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer Who Have Received Two or Three Prior Systemic Chemotherapy Regimens
- Lead sponsor
- Compass Therapeutics
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 8, 2022
- Completion date
- May 15, 2025
- Enrollment
- 49 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
colon cancer, metastatic colorectal cancer, rectal cancer